Press Releases 3SBio Inc.

Equities

1530

KYG8875G1029

Delayed Hong Kong S.E. Other stock markets 11:29:07 2024-04-28 pm EDT			5-day change	1st Jan Change
6.23 ^HKD	+2.47%		+11.81%	-16.89%

Apr. 22	3Sbio Inc. Announces Management Changes	CI
Apr. 15	3SBIO Gets China Nod for Use of Cancer Injection in Children with Thrombocytopenia	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

3SBio announces 2023 interim results, with revenue growing over 20% year on year and pipeline value constantly enhanced	23-08-24	PR
3SBio : 2023 Interim Results Presentation	23-08-24	PU
3SBio : 2022 ESG Report	23-04-28	PU
3SBio announces 2022 annual results, with revenue rising 7.5% year on year and normalized net profit attributable to parents jumping 25.2%	23-03-21	PR
3SBio : 2022 Interim Results Presentation	22-08-24	PU
3SBio : 1530.HK) _ Prospectus	22-06-24	PU
3SBio : 2021 ESG Report	22-05-24	PU
3SBio : 2021Annual Report	22-04-29	PU
3SBio : announces 2021 annual results, with net profit attributable to owns of the parents almost doubling under accelerated growth of diversified businesses	22-03-30	PU
3SBIO : 2021Annual Results	22-03-28	PU
3SBio : Documents on Display	21-12-21	PU
3SBio : announces 2021 interim results, with strong growth in core businesses and significant progress in clinical development	21-08-26	PU
3SBio : announces 2020 annual results, tapping integrated platform advantages for steady growth	21-03-30	PU
3SBio : PRELIMINARY RESULTS OF SUNSHINE GUOJIAN PHARMACEUTICAL (SHANGHAI) CO., LTD. FOR THE YEAR ENDED 31 DECEMBER 2020	21-02-26	PU
3SBio : Sunshine Guojian Selects Verseau’s VSIG4-targeted Antibody as the Second Partnered Macrophage Checkpoint Modulator in Immuno-Oncology Collaboration	20-12-14	PU
3SBio Inc. : received milestone payment of USD 4 million upon commencement of phase III clinical program of SEL-212	20-11-23	PR
3SBio : Announces Acceptance of IND application for bevacizumab biosimilar in China	20-09-14	PU
3SBio : VOLUNTARY ANNOUNCEMENT - ACCEPTANCE OF THE IND APPLICATION FOR BEVACIZUMAB BIOSIMILAR IN MAINLAND CHINA	20-09-14	PU
3SBio : MSCI ESG Rating Upgraded to A, Ranking at the Forefront of the Global Biotechnology Industry	20-09-01	PU
3SBio : WITHDRAWAL OF LISTING OF THE ZERO COUPON CONVERTIBLE BONDS DUE 2022	20-08-28	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases 3SBio Inc.

Equities

1530

KYG8875G1029

Press Releases

Filters